PAVmed Inc. plans to submit its Varis implantable physiological monitor for FDA approval by the end of 2026 [1].
The timeline represents a critical pivot for the company as it seeks to transition from corporate restructuring to commercial product development. Success with the Varis platform would allow the company to enter the physiological monitoring market with a proprietary device.
During a first-quarter 2026 earnings call, the company detailed its current operational focus. PAVmed is now prioritizing the Varis program while simultaneously evaluating new assets to expand its portfolio [1], [2]. This strategic shift follows a two-year restructuring process designed to simplify the company's financial foundation [3].
As part of this cleanup, PAVmed simplified its capitalization table. The company's capital structure now consists solely of common stock [3]. This move was intended to streamline ownership, and prepare the firm for its next phase of growth.
Beyond its internal device development, PAVmed maintains an investment in other health technology. The company holds approximately 15% of the outstanding common shares, and 25% of the voting interest in Lucid Diagnostics [3].
Management said the company is continuing to assess additional assets that align with its core mission. The focus remains on the Varis submission deadline as the primary milestone for the 2026 calendar year [1], [2].
“PAVmed plans to submit its Varis implantable physiological monitor for FDA approval by the end of 2026”
By eliminating complex preferred shares and consolidating into common stock, PAVmed has removed financial hurdles that often complicate venture funding or acquisitions. The move to target a late 2026 FDA submission suggests the company is moving out of its restructuring phase and into a high-risk, high-reward regulatory window where its valuation will depend almost entirely on the Varis monitor's approval.
